Treatment of Spinal Cord Injury with Olfactory Mucosa Autgrafts in Human Spinal Cord Injury : Phase 1 and 2 Clinical Study

Treatment of Spinal Cord Injury with Olfactory Mucosa Autgrafts in Human Spinal Cord Injury : Phase 1 and 2 Clinical Study - Olfactory Mucosa Autgrafts(MP0603)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000825

Enrollment

Registered

2007-09-14

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury

Interventions

Olfactory Mucosa Autografts(+) Fasudil Hydrochloride Hydrate(+) Olfactory Mucosa Autografts(+) Fasudil Hydrochloride Hydrate(-)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.ASIA or Frankel A or B. 2.MRI :The length of the injury part doesn't exceed 3 cm and be single. 3.CT :It doesn't admit an intranasal. 4.MRSA and MRSE isn't detected. 5.The sense of smell is normal. 6.The equal to or more than 6 month elapse after carrier wound.

Exclusion criteria

Exclusion criteria: 1.It bleeds at the spinal cord. 2.Mental disease. 3.Alcohol dependence 4.Consciousness disorder. 5.Malignant tumor/ 6.HIV, HBV, HCV, HTLV, CMV,syphilis. 7.Liver or Renal fault. 8.Respiratory fault. 9.Hypotension. Diabetes. 10.When judged not to suit

Design outcomes

Primary

Measure	Time frame
Safety infection and malignant neoplasm	—

Secondary

Measure	Time frame
Effeicacy ASIA scoring,SSEP,MEG,MEP urinary function	—

Countries

Japan

Contacts

Public ContactKoichi Iwatsuki

Osaka University Medical School Department of Neurosurgery

kiwatsuki@nsurg.med.osaka-u.ac.jp06-6879-3652

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026